Pediatric Phase 3 study results for XLH-related rickets, lower extremity abnormalities, growth, and serum phosphorus
Learn more about the CRYSVITA safety profile
CRYSVITA dosing and administration recommendations and dosing calculator
Understand how CRYSVITA works
XLH IN PEDIATRIC PATIENTS
- XLH is the most common cause of inherited phosphorus wasting and leads to poor bone mineralization.1-3
- Consequentially, patients with XLH can be impacted by XLH-related rickets, osteomalacia, shorter height, lower extremity abnormalities (genu varus, “bowed legs”; genu valgum, “knock knees”; windswept deformity), and a reduced quality of life.1,2
Data for CRYSVITA on serum phosphate levels, XLH-related rickets, lower extremity skeletal abnormality, and height in pediatric patients with XLH are presented elsewhere in this website. CRYSVITA’s effects on osteomalacia in children and adolescents, and quality of life in all age ranges have not been evaluated as predefined endpoints in clinical trials.
References: 1. Haffner D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435-455. 2. Dahir K, et al. X-linked hypophosphatemia: A new era in management. J Endocr Soc. 2020;4(12):bvaa151. 3. Glorieux FH, et al. Potential influences on optimizing long-term musculoskeletal health in children and adolescents with X-linked hypophosphatemia (XLH). Orphanet J Rare Dis. 2022;17(1):30.
